Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 ·
Decision snapshot: DOC stock price vs QRVO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QRVO's multiple
Needs QRVO P/E.
Implied fair value · at DOC's multiple
Needs DOC P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DOC FY 2025 (ended Dec 31, 2025) · QRVO FY 2026 (ended Mar 28, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 59% equity / 41% debt · EV / Revenue 8.37x · EV / EBITDA 36.57x
Capital structure 85% equity / 15% debt · EV / Revenue 2.55x · EV / EBITDA 11.63x
DOC carries the larger enterprise value at $23.62B against $9.38B; QRVO trades on the lower EV / Revenue multiple (2.55x vs 8.37x); QRVO on the lower EV / EBITDA (11.63x vs 36.57x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Healthpeak Properties, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Qorvo, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.31x
0.46x
Net debt / EBITDA
Leverage against operating earnings
14.52x
0.41x
Cash and equivalents
Liquid reserves on the balance sheet
$467.46M
$1.22B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
WELLTOWER INC.
DOC vs WELL
Ventas, Inc.
DOC vs VTR
ALEXANDRIA REAL ESTATE EQUITIES, INC.
DOC vs ARE
SL GREEN REALTY CORP
DOC vs SLG
SKYWORKS SOLUTIONS, INC.
DOC vs SWKS
Broadcom Inc.
DOC vs AVGO
Marvell Technology, Inc.
DOC vs MRVL
ON SEMICONDUCTOR CORP
DOC vs ON
NXP Semiconductors N.V.
DOC vs NXPI
TEXAS INSTRUMENTS INC
DOC vs TXN
$9.85B
$1.55B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DOC can materially improve profitability and de-lever quickly enough to justify a premium multiple, then hold; otherwise, the data argues for a cautious or underweight stance because DOC trades far above both QRVO-implied and DCF ranges while carrying weaker margins and much higher leverage.
DOC trades at a large premium to QRVO on both earnings and sales multiples, despite materially weaker net income and margin profile. The implied price from QRVO P/E comparison is $2.42 versus DOC’s current price of $21.89, indicating an 88.9% downside under that framework.
Supporting Metrics
